Eliminating Helicobacter pylori May Significantly Decrease Gastric Cancer Risk
December 13, 2019
Successfully eliminating Helicobacter pylori from a patient’s gastrointestinal tract could lead to a significant decrease in gastric cancer risk.
Recent Content
True Acupuncture Shows Promise for Patients with Head and Neck Cancer
December 13, 2019
True acupuncture resulted in fewer and less severe radiation-induced xerostomia symptoms in this phase III study.
Andre H. Goy, MD, MS, Discusses Extending Survival for Patients with DLBCL
December 13, 2019
Andre H. Goy, MD, MS, from Hackensack University Medical Center, discussed ways to address the extension of survival for patients with DLBCL who achieved a complete remission at the ASH Annual Meeting & Exposition.
John M. Pagel, MD, PhD, on Polatuzumab Vedotin
December 13, 2019
The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting & Exposition.
Stephen M. Hahn, MD, Confirmed as FDA Commissioner
December 12, 2019
Stephen M. Hahn, MD, from The University of Texas MD Anderson Cancer Center, will take over as Commissioner of the FDA, voted on by the Senate on Thursday.
Stephen M. Ansell, MD, PhD, on Progress of CAR T-Cell Therapy
December 12, 2019
The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.
KTE-X19 CAR T-Cell Therapy Effective for Relapsed/Refractory Mantle Cell Lymphoma
December 12, 2019
The ZUMA-II trial suggested that patients with relapsed/refractory mantle cell lymphoma resistant to prior therapies may benefit from the autologous anti-CD19 CAR T-cell therapy.
Long-Term Follow-Up Supports Anastrozole Treatment to Prevent Breast Cancer Recurrence
December 12, 2019
Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up.
Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer
December 11, 2019
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.
Addition of Pertuzumab to Previous Standards Improves IDFS in HER2+ Breast Cancer
December 11, 2019
The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis.
